Sorafenib is an oral multikinase inhibitor that inhibits several receptor tyrosine kinases and can inhibit tumor growth by influencing angiogenesis, tumor proliferation, and apoptosis.6 Since 2007, it has become the standard first-line treatment for advanced HCC. Here, NTRK1 is linked to neoplasm.